SecBot SecBot
6-K ·Filed Nov 10, 2026

ALC

ALCON INC
NEUTRAL
Impact 5/10
Horizonweeks Processed6d 6h ago SEC0001167379-26-000033
6-K: Earnings release
Actionable Insight • Neutral

Alcon's Q3 results met consensus with steady 5% revenue growth and 15% core EPS growth, while the tightened full-year guidance suggests management sees stable near-term trends. Watch for the impact of the Neurotech acquisition on the Vision Care retina portfolio and any further tariff developments, as the company expects a net $40M tariff impact for the full year.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$72.46
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.87%
T+1 · $71.83
Vs SPY
−0.52%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 11 $72.46entry
  2. T+1 · 5d ago −0.87%α −0.52% · $71.83
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alcon reported Q3 2026 net sales of $2.717B, up 5% YoY, and core diluted EPS of $0.91, up 15% YoY, both in line with consensus estimates of $2.74B and $0.89. The company tightened its full-year 2026 outlook, narrowing constant-currency net sales growth to +6%, core operating margin expansion to +100-150 bps, and core EPS growth to +12-14%. The quarter benefited from tariff refunds and strong product launches, while the nine-month IFRS results were impacted by a $505M impairment charge related to the PowerVision program discontinuation.

Key Financial Metrics

EPS (Adj.)
$0.91
est $0.89 · +2.3% · GAAP: $0.54
Revenue
$2.7B
est $2.7B · -0.8% · +4.9% YoY
Rating
beat
Guidance
+6% cc vs prior year
maintained
Free Cash Flow
$1.3B
Gross Margin
59.7%

Key Facts

  • Q3 2026 net sales $2.717B, +5% YoY (in line with $2.74B consensus)
  • Q3 2026 core diluted EPS $0.91, +15% YoY (in line with $0.89 consensus)
  • Q3 2026 GAAP diluted EPS $0.54, +13% YoY
  • Full-year 2026 outlook tightened: cc net sales growth +6%, core operating margin +100-150 bps, core EPS growth +12-14%
  • Q3 2026 Vision Care segment contribution +24% YoY, Surgical +7% YoY
  • Q3 2026 gross margin 59.7% vs 56.3% YoY; core gross margin 65.7% vs 62.9% YoY
  • Nine-month 2026 operating income $684M (-35% YoY) due to $505M PowerVision impairment
  • Free cash flow $1.345B for nine months 2026 vs $1.244B prior year
  • Acquired Neurotech Pharmaceuticals for $550M closing consideration in October 2026
  • $1.0B remaining on $1.5B share repurchase authorization as of Sept 30, 2026

Financial Impact

Q3 2026 net sales $2.717B, core diluted EPS $0.91; full-year guidance tightened to +6% cc sales growth, +12-14% cc core EPS growth

revenueepsoperating marginfree cash flow

Segment Breakdown

SegmentRevenueGrowth
Surgical$1.5B+4.2%
Vision Care$1.2B+5.8%

Risk Factors

  • U.S. IOL competitive pressures continue, with implantables down 2% in Q3
  • Full-year tariff impact of ~$40M net of refunds, with uncertainty on future tariff policy
  • PowerVision program discontinuation resulted in $505M impairment; contingent consideration liabilities remain up to $1.0B
  • Nine-month GAAP operating income down 35% YoY due to impairment charges

Market Snapshot

Exchange
NYSE
Sector
Ophthalmic Goods
Analyst Consensus
73% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001167379-26-000033
Document: q32026pressrelease.htm0001167379-26-000033
Document: form6-kxearningsreleaseand.htm0001167379-26-000033
Document: 0001167379-26-000033-index-headers.html0001167379-26-000033
Document: 0001167379-26-000033-index.html0001167379-26-000033
Document: 0001167379-26-000033.txt0001167379-26-000033
Earnings Context (Synthetic; results releases only)0001167379-26-000033

Track record

5 reports on ALC

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.74% at T+5 after the Jun 26, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 5/10 Viewing Entry $72.46 Now $73.64 +1.63% settles Feb 9
  2. Nov 6, 202610d ago Institutional Cluster Mixed 3/10 Entry $74.94 Now $73.64 −1.73% settles Feb 4
  3. Aug 10, 202614w ago 6-K Bullish 6/10 Entry $75.35 to $77.31 Now $73.64 −2.27% ▲ +2.60% +3.09% vs SPY
  4. Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.61 to $65.39 Now $73.64 +8.92% ▼ −3.28% −6.90% vs SPY
  5. Jun 26, 202620w ago Court Ruling Bullish 5/10 Entry $67.80 to $64.87 Now $73.64 +8.61% ▼ −4.32% −8.81% vs SPY
Showing 5 of 5

US Market Status

Market Closed · Opens Wed (10h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026